Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds HC Wainwright & Co. Downgrades Vascular Biogenics to Neutral

HC Wainwright & Co. Downgrades Vascular Biogenics to Neutral

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

byBenzinga Newsdesk

July 20, 2022

1 minute read

HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Vascular Biogenics (NASDAQ:VBLT) from Buy to Neutral.

Analyst Ratings

Where Verastem Stands With Analysts

By Benzinga Insights

November 15, 1:01 PM

Verastem (NASDAQ:VSTM) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

VSTM

Cannabis MSO Exists Arizona, Analyst Calls It ‘A Good Move’ And Here’s Why

By Jelena Martinovic

March 28, 1:46 PM

Cannabis company AYR Wellness Inc. (CSE: AYR.A) (OTCQX: AYRWF) has closed the sale of Blue Camo, LLC, which comprises the company's Arizona assets, to AZ Goat AZ, LLC, a group consisting primarily of the former owners of B

AYRWF

What’s Going On With Crown Castle Stock Thursday?

By Adam Eckert

October 19, 11:33 AM

Crown Castle Inc (NYSE: CCI) shares are trading lower Thursday after the company reported third-quarter financial results.

CCI

Rosenblatt Maintains Buy on Ansys, Raises Price Target to $310

By Benzinga Newsdesk

February 27, 8:18 AM

Rosenblatt analyst Blair Abernethy maintains Ansys (NASDAQ:ANSS) with a Buy and raises the price target from $270 to $310.

ANSS

HC Wainwright & Co. Downgrades Vascular Biogenics to Neutral

Related Posts

Where Verastem Stands With Analysts

Cannabis MSO Exists Arizona, Analyst Calls It ‘A Good Move’ And Here’s Why

What’s Going On With Crown Castle Stock Thursday?

Rosenblatt Maintains Buy on Ansys, Raises Price Target to $310